149.27
5.69 (3.96%)
| Previous Close | 143.58 |
| Volume | 367,600 |
| Price / Sales | 5.48 |
| Price / Book | 3.38 |
| 52 Weeks Range |
| Profit Margin | 7.42% |
| Operating Margin (TTM) | 12.84% |
| Diluted EPS (TTM) | 1.95 |
| Quarterly Revenue Growth (YOY) | 1.10% |
| Quarterly Earnings Growth (YOY) | 44.50% |
| Total Debt/Equity (MRQ) | 57.49% |
| Current Ratio (MRQ) | 2.56 |
| Operating Cash Flow (TTM) | 157.37 M |
| Levered Free Cash Flow (TTM) | 152.43 M |
| Return on Assets (TTM) | 5.75% |
| Return on Equity (TTM) | 9.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Scientific & Technical Instruments (US) | Mixed | Bullish |
| Scientific & Technical Instruments (Global) | Mixed | Bullish | |
| Stock | Novanta Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
|
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States. |
|
| Sector | Technology |
| Industry | Scientific & Technical Instruments |
| Investment Style | Small Growth |
| % Held by Insiders | 0.86% |
| % Held by Institutions | 105.06% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |